#APASL2023 Archives - MediaMedic

APASL 2023 | Prof. Hu Jinhua: Liver Cell Regeneration and Its Application in Liver Failure Treatment

By Peter W. PENG 2024.01.04

Editor's Note: At the 32nd Asia-Pacific Association for the Study of the Liver (APASL) annual conference, Professor Hu Jin-Hua from the Department of Hepatology at the Fifth Medical Center of…

APASL 2023 | Prof. Ji Dong: Clinical Characteristics of Elderly Drug-Induced Liver Injury Combined with Autoimmune Phenomena

By Mourabit Halima 2024.01.03

Editor's Note: In recent years, with the increase in health awareness, the incidence of drug-induced liver injury (DILI) has been rising. Immune responses can trigger inflammation and necrosis, leading to…

APASL 2023 | Prof. George Lau: Seeking the “Cure” for Liver Disease – A Hepatologist’s Thirty-Year Journey of Exploration

By Mourabit Halima 2024.01.03

Editor's Note: The 32nd annual meeting of the Asia-Pacific Association for the Study of the Liver (APASL) was held at the Taipei International Convention Center in Taiwan, China, from February…

APASL 2023 | Prof. Ning Qin: Treatment of ACLF with Infection and Its Impact on Liver Transplantation

By Lisa Cui 2024.01.03

Editor's Note: Acute-on-chronic liver failure (ACLF) refers to a syndrome where, on the basis of chronic liver disease, the patient experiences a rapid deterioration of liver function within a short…

APASL 2023 | Prof. Ning Qin: New Strategies for Targeting Liver Autophagy Abnormalities in Fatty Liver Disease Interventions

By Mourabit Halima 2024.01.03

Editor's Note: In recent years, the global incidence of Non-Alcoholic Fatty Liver Disease (NAFLD) has been continuously rising, becoming the most common cause of chronic liver disease worldwide, with an…

APASL 2023 | Prof. Wu Chao: Metabolic Predictors and Liver Fibrosis Diagnostic Model Construction for Chronic Hepatitis B Combined with NAFLD

By Mourabit Halima 2024.01.03

Editor's Note: Chronic hepatitis B (CHB) is the primary cause of chronic liver disease in China and other Asian countries, as well as a major contributor to liver-related morbidity and…

APASL 2023 | Prof. Hou Jinlin: The New Hepatitis B Drug ALG-000184 Combined with Entecavir Shows Stronger Antiviral Activity Than Entecavir Alone

By Mourabit Halima 2024.01.03

Editor's Note: Chronic hepatitis B virus (HBV) infection is a global epidemic, yet we still lack a treatment that can completely conquer HBV. At present, most patients still need long-term…